Article

Know the Basics: Mantle Cell Lymphoma

Author(s):

Brielle Benyon

This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.

While is a type of blood cancer, there are actually many subtypes of the disease that can be broken into two main categories: Hodgkin lymphoma and non-Hodgkin lymphoma. From there, diseases can be categorized even further out. For example, mantle cell lymphoma is a type of B-cell non-Hodgkin lymphoma.

Current Food and Drug Administration (FDA)-approved treatments for mantle cell lymphoma include:

  • Chemotherapy
  • Proteasome inhibitors
  • Stem cell transplants
  • Surveillance

However, new treatments, such as chimeric antigen receptor (CAR)-T cell therapy and immunotherapy, are also being explored in clinical trials, and could eventually become a promising and effective treatment for the disease.

Related Videos
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Cirmtuzumab Combinations Show Potential in Treatment of Mantle Cell Lymphoma
Related Content
Dr. Tycel Phillips discusses the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL. | © Digilife - stock.adobe.com
February 11th 2025

FDA Approval of Calquence Combo Brings Optimism in MCL

Ryan Scott
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL: © Zhanna - stock.adobe.com
February 5th 2025

FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL

Ryan Scott
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor approved for first line therapy.
FDA Approved Image.
February 3rd 2025

Breaking Down Cancer Therapies Approved by the FDA in January 2025

Ryan Scott
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.
Image of 'FDA Approval'
January 16th 2025

FDA Approves Calquence Combo for Mantle Cell Lymphoma

Alex Biese
The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some patients with MCL.
Illustration of cross hairs on cancer in the blood.
December 16th 2024

Tecartus After Outpatient Lymphodepletion Safe, Effective in B-ALL and MCL

Chris Ryan
Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.
Illustration of mantle cell lymphoma cells.
December 11th 2024

Survival Outcomes Not Improved With Autologous Stem Cell Transplant in MCL

Gina Mauro
Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.